- WuXi Biologics has launched TrueSite TI™, a targeted integration-based CHO cell line platform, as the fourth generation of its WuXia™ system.
- The platform shortens IND timelines to six months and supports scalable commercial manufacturing with high-yield, stable cell lines.
WuXi Biologics has announced the launch of TrueSite TI™, a targeted integration (TI)-based CHO cell line platform designed to streamline biologics development. The new system aims to accelerate development timelines, improve product quality, and ensure stable scalability for antibody and complex protein therapies.
TrueSite TI™ represents the fourth generation of the company’s WuXia™ cell line platform, which has supported more than 1,000 molecules over the past decade. The new version leverages precision cellular engineering, placing expression units in validated genomic locations. This approach reduces clone screening requirements, enhances expression stability, and enables investigational new drug (IND) submissions in as little as six months.
The platform has achieved an average monoclonal antibody titer of more than 8.0 g/L. It also maintains over 99% stability of clonal cell lines after 60 generations, supporting scale-up to 20,000 litres. While designed for monoclonal antibodies, TrueSite TI™ is also applicable to bispecific antibodies, Fc-fusion proteins, and Fab fragments.
“With biopharmaceutical companies striving to bring high-quality, life-saving therapies to patients faster, cell line development stands as the critical point in achieving this mission. WuXi Biologics continues to advance its WuXia™ platform, pushing the boundaries of cell line development.”
Dr Chris Chen, CEO of WuXi Biologics
The WuXia™ platform family includes systems such as WuXiaADCC Plus™ for afucosylated antibodies, WuXia RidGS™ for non-antibiotic cell line development, and WuXia293 Stable™ for expressing difficult molecules. With TrueSite TI™, the company further extends its CDMO and contract manufacturing capabilities to meet global client needs in biologics development.
